Published in J Natl Compr Canc Netw on July 01, 2015
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol (2007) 5.13
Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 4.01
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol (2009) 1.95
PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol (2013) 1.92
Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res (2003) 1.64
Epithelial ovarian cancer. J Natl Compr Canc Netw (2011) 1.16
Ovarian cancer, version 2.2013. J Natl Compr Canc Netw (2013) 1.13
Ovarian cancer, version 3.2012. J Natl Compr Canc Netw (2012) 1.08
Psychosocial issues in adolescents with cancer. Cancer Treat Rev (2007) 1.08
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.06
Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med (2009) 1.05
Caring for one of our own. Oncologist (2014) 1.04
Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol (2009) 1.01
Epithelioid angiosarcoma of the uterus: a review of management. Arch Gynecol Obstet (2008) 1.01
A phase II, single-arm study of the anti-α5β1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol (2011) 1.01
Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol (2010) 1.00
Breaking bad news: a patient's perspective. Oncologist (2003) 1.00
Direct-to-consumer advertising in oncology. Oncologist (2006) 0.97
Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management. J Allergy Clin Immunol (2009) 0.96
Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors. Cancer (2013) 0.95
Case records of the Massachusetts General Hospital. Case 8-2010. A 22-year-old woman with hypercalcemia and a pelvic mass. N Engl J Med (2010) 0.93
Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol (2010) 0.92
A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol (2004) 0.91
Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol (2008) 0.91
Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr Cancer Ther (2010) 0.91
Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol (2008) 0.90
Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A (2013) 0.89
Panniculitis associated with dermatomyositis and recurrent ovarian cancer. Arch Dermatol (2012) 0.89
Living as a cancer surpriser: a doctor tells his story. Oncologist (2003) 0.88
Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer. Int J Gynecol Cancer (2012) 0.87
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clin Ovarian Cancer Other Gynecol Malig (2011) 0.87
beta tubulin mutations are rare in human ovarian carcinoma. Anticancer Res (2003) 0.86
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol (2012) 0.85
A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol (2005) 0.83
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol (2012) 0.82
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol (2009) 0.80
Cone damage in patients receiving high-dose irofulven treatment. Arch Ophthalmol (2005) 0.79
Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol (2003) 0.78
Faith, identity, and leukemia: when blood products are not an option. Oncologist (2002) 0.78
Vintafolide (EC145) for the treatment of folate-receptor-α positive platinum-resistant ovarian cancer. Expert Rev Clin Pharmacol (2014) 0.78
Learning to cope: how far is too close? Oncologist (2005) 0.77
Ovarian stromal and germ cell tumors. Semin Oncol (2009) 0.76
Sugar fuels cancer. Cancer (2009) 0.75
Cycles within cycles. Menopause (2008) 0.75
Detection of residual subclinical ovarian carcinoma after completion of adjuvant chemotherapy. Clin Cancer Res (2004) 0.75
Complexions of compliance. Menopause (2013) 0.75
Emerging therapeutic options for platinum-sensitive ovarian cancer patients. Clin Adv Hematol Oncol (2011) 0.75
Silence as the speech of care. J Support Oncol (2004) 0.75